We speculate that uveitis previously induced by avelumab caused immune dysregulation, making the patient predisposed to developing irAEs even when switching back to pembrolizumab, despite the differences in their mechanisms (PD-1 inhibitor and PD-L1 inhibitor). This evidence concerns the gene PDCD1 and uveitis.